Inogen has signed a definitive agreement for the acquisition of France-based company Physio-Assist in a deal valued at nearly $45m, to bolster its respiratory product portfolio.

Physio-Assist created and produces a technology-facilitated airway clearance device, Simeox.

This device is presently used outside the US for treating bronchiectasis, a lung ailment, in pulmonary rehabilitation centres and at-home settings. 

The bronchi of the lungs become injured and enlarged in this condition, which is frequent in cystic fibrosis and chronic obstructive pulmonary disease. 

Simeox has received clearance in the European Union under the CE mark and is marketed in Europe, the Middle East and Asia (EMEA).

As per the deal, Physio-Assist is entitled to receive nearly $32m in cash from Inogen at closing, as well as payments on meeting milestones linked to clearance from the Food and Drug Administration for the device. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The board of directors of both companies have approved the deal.

Inogen president and CEO Nabil Shabshab said: “This acquisition aligns with our strategy to diversify our portfolio to globally improve patient lives through respiratory care. 

“Simeox imminently expands our product offering in EMEA and potentially in the US to serve COPD and other chronic disease patients who suffer from bronchiectasis with an innovative, non-invasive and next-generation airway clearance solution.”

Subject to necessary conditions and approvals, the acquisition is anticipated to conclude in the fourth quarter of this year.